Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H19F2N7O |
Molecular Weight | 399.3973 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N=CN=C1COC2=NN3C(C=C2C(C)(C)C)=NN=C3C4=CC(F)=CC=C4F
InChI
InChIKey=BQDUNOMMYOKHEP-UHFFFAOYSA-N
InChI=1S/C19H19F2N7O/c1-19(2,3)13-8-15-24-25-17(12-7-11(20)5-6-14(12)21)28(15)26-18(13)29-9-16-22-10-23-27(16)4/h5-8,10H,9H2,1-4H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10816315Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23664899
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10816315
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23664899
L-838,417 is a subtype-selective GABAA modulator, acting as a partial agonist at alpha2, alpha3 and alpha5 subtypes and an antagonist at the alpha1 subtype. L-838,417 displays anxiolytic effects in vivo and is used as a tool compound to study roles of GABAA subunits.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094122 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10816315 |
2.25 nM [Ki] | ||
Target ID: CHEMBL2094130 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10816315 |
0.67 nM [Ki] | ||
Target ID: CHEMBL2094120 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10816315 |
0.67 nM [Ki] | ||
Target ID: CHEMBL2094121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10816315 |
79.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23664899
In the model of anxiety L-838,417 was dissolved in a (2-Hydroxypropyl)-beta-cyclodextrin solution and administered intraperitoneally (i.p.) at a volume of 2 ml/kg to male and female adolescent and adult SD rats. Anxiolytic effect of L-838,417 was demonstrated at doses 1-4 mg/kg.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10816315
Curator's Comment: Methods from https://www.ncbi.nlm.nih.gov/pubmed/9185540
Electrophysiological experiments on were performed on Ltk- cells expressing human cDNA combinations a1b3g2s, a2b3g2s, a3b3g2s and a5b3g2s. Glass coverslips containing the cells in a monolayer culture were transferred to a chamber on the stage of an inverted microscope. Cells were perfused continuously with a solution containing (in mM): 124 NaCl, 2 KCl, 2 CaCl2, 1 MgCl2, 1.25 KH2PO4, 25 NaHCO3, and 11 d-glucose, pH 7.2, and observed with phase-contrast optics. Patch pipettes were pulled with an approximate tip diameter of 2 μm and a resistance of 4 MΩ with borosilicate glass and were filled with (in mM): 130 CsCl, 10 HEPES, 10 EGTA, and 3 Mg+-ATP, pH-adjusted to 7.3 with CsOH. Cells were patch-clamped in whole-cell mode with a List LM-EPC 7 patch-clamp amplifier. Drug solutions were applied by a double-barreled pipette assembly, which was controlled by a stepping motor attached to a Prior manipulator, enabling rapid equilibration around the cell. Increasing GABA concentrations were applied for 10 sec pulses with a 30 sec interval between applications.
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9908880
Created by
admin on Sat Dec 16 08:16:53 GMT 2023 , Edited by admin on Sat Dec 16 08:16:53 GMT 2023
|
PRIMARY | |||
|
8CZO0970G3
Created by
admin on Sat Dec 16 08:16:53 GMT 2023 , Edited by admin on Sat Dec 16 08:16:53 GMT 2023
|
PRIMARY | |||
|
L-838,417
Created by
admin on Sat Dec 16 08:16:53 GMT 2023 , Edited by admin on Sat Dec 16 08:16:53 GMT 2023
|
PRIMARY | |||
|
DTXSID90432710
Created by
admin on Sat Dec 16 08:16:53 GMT 2023 , Edited by admin on Sat Dec 16 08:16:53 GMT 2023
|
PRIMARY | |||
|
286456-42-6
Created by
admin on Sat Dec 16 08:16:53 GMT 2023 , Edited by admin on Sat Dec 16 08:16:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY